Beam Therapeutics (BEAM) Stock Forecast & Price Target

$26.84 -1.46 (-5.16%)

(As of 12:02 PM ET)

Beam Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
4

Buy
8

Based on 12 Wall Street analysts who have issued ratings for Beam Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for BEAM.

Consensus Price Target

$44.91
67.32% Upside

According to the 12 analysts' twelve-month price targets for Beam Therapeutics, the average price target is $44.91. The highest price target for BEAM is $80.00, while the lowest price target for BEAM is $24.00. The average price target represents a forecasted upside of 67.32% from the current price of $26.84.

Get the Latest News and Ratings for BEAM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Beam Therapeutics and its competitors.

BEAM Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$44.91	$45.80	$41.70	$48.80
Forecasted Upside	67.32% Upside	99.74% Upside	73.17% Upside	65.09% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

The indicator behind Nvidia’s rally has a new prospect (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

BEAM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BEAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Beam Therapeutics Stock vs. The Competition

Type	Beam Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	65.59% Upside	25,916.81% Upside	7.05% Upside
News Sentiment Rating	Positive News See Recent BEAM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	HC Wainwright 2 of 5 stars	P. Trucchio Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+200.53%
11/6/2024	Leerink Partnrs 5 of 5 stars	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/6/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Sector Perform ➝ Sector Perform	$27.00 ➝ $24.00	-9.30%
11/6/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$27.00 ➝ $39.00	+62.98%
11/5/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$57.00	+138.19%
10/16/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$24.00	-8.88%
Get the Latest News and Ratings for BEAM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/11/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$66.00 ➝ $69.00	+191.75%
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$45.00 ➝ $48.00	+94.88%
8/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$33.00 ➝ $31.00	+26.69%
3/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00	+68.29%
12/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$35.00	+17.49%
12/8/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$75.00 ➝ $30.00	+4.35%
10/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/20/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $47.00	+80.01%
8/9/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$60.00 ➝ $56.00	+113.33%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$37.00	+14.80%
3/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$125.00 ➝ $105.00	+160.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:25 PM ET.

BEAM Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Beam Therapeutics is $44.91, with a high forecast of $80.00 and a low forecast of $24.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BEAM shares.
: According to analysts, Beam Therapeutics's stock has a predicted upside of 67.32% based on their 12-month stock forecasts.
: Over the previous 90 days, Beam Therapeutics's stock had 2 upgrades by analysts.
: Beam Therapeutics has been rated by research analysts at HC Wainwright, Leerink Partners, Leerink Partnrs, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, and Wedbush in the past 90 days.
: Analysts like Beam Therapeutics less than other "medical" companies. The consensus rating score for Beam Therapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BEAM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

My most important prediction yet (Ad)

One year ago at this time, I was gearing up to do something I’d never done before… After years of working behind the scenes, helping Tom Busby and teaching traders all about the markets, I was about ready to jump in front of a camera. Why? Because my research and years of expertise were showing me a phenomenon that people NEEDED to know about. That gold was setting up to go on a historic run that I called the “2024 Gold Supercycle.” I went LIVE on December 7, 2023, and made my bold prediction — staking 20+ years of a reputation on this one public prognostication. And the rest, as they say, is history… Gold went on to have its best year since 1979 — almost half a century! I’m going to tell you all about it on Wednesday, December 4th @ 1:00 PM ET, 362 days after I first made my prediction on gold.

Go here and finish your registration to receive your access link

This page (NASDAQ:BEAM) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Stock Forecast & Price Target